Approach to Hematuria for NAC OSCE Canada
For the NAC OSCE, immediately distinguish between gross and microscopic hematuria, then risk-stratify microscopic hematuria patients using age, smoking history, degree of hematuria, and history of gross hematuria to determine the appropriate evaluation pathway. 1
Initial Assessment
When encountering hematuria, perform these specific evaluations:
History - Key Elements
- Smoking exposure: Quantify pack-years (critical cancer risk factor) 2
- Gross hematuria history: Even if self-limited, this elevates risk 2
- Associated symptoms:
- Flank pain/renal colic suggests stones
- Painless gross hematuria suggests malignancy 2
- Medications: Anticoagulants/antiplatelets (do NOT defer evaluation based on these) 2
- Occupational exposures: Chemical/dye industry
- Family history: Urologic malignancies
Physical Examination Specifics
- Blood pressure measurement (renal disease screening)
- Abdominal/flank examination
- Digital rectal exam in men (prostate assessment)
Laboratory Confirmation
Critical first step: Confirm dipstick-positive results with microscopic urinalysis showing ≥3 RBCs/HPF before proceeding with further evaluation 2, 1. This prevents unnecessary workups from false-positive dipsticks.
Risk Stratification Algorithm (2025 AUA/SUFU)
Use this three-tier system to guide management 1:
Low/Negligible Risk (ALL criteria must be met):
- 3-10 RBC/HPF
- Women <60 years OR Men <40 years
- Never smoker or <10 pack-years
- Action: Shared decision-making; may defer cystoscopy and imaging
Intermediate Risk (ONE or more):
- 11-25 RBC/HPF
- Women ≥60 years OR Men 40-59 years
- 10-30 pack-years smoking history
- Action: Ultrasound kidneys + cystoscopy
High Risk (ONE or more):
25 RBC/HPF
- Men ≥60 years
30 pack-years smoking history
- History of gross hematuria (even if current UA shows only 3-25 RBC/HPF)
- Action: CT urography + cystoscopy
Management Pathways
Gross Hematuria
Refer ALL patients for urgent urologic evaluation regardless of whether it resolved 2. Cancer risk exceeds 10-25% in referral series 2.
Microscopic Hematuria
Do NOT order 2:
- Urinary cytology (not recommended for initial evaluation)
- Urine molecular markers for bladder cancer
Evaluation components based on risk tier:
Intermediate Risk:
- Renal ultrasound (upper tract imaging)
- Cystoscopy (bladder visualization)
High Risk:
- CT urography with contrast (optimal upper tract imaging)
- Cystoscopy
- Consider MR urography if CT contraindicated
Common Pitfalls to Avoid
Do NOT screen asymptomatic adults with urinalysis for cancer detection 2 - this creates unnecessary downstream testing
Do NOT defer evaluation in patients on anticoagulation/antiplatelet therapy 2 - these medications do not cause hematuria, they unmask underlying pathology
Do NOT accept dipstick alone - always confirm with microscopy showing ≥3 RBC/HPF 2
Do NOT ignore self-limited gross hematuria - still requires full evaluation 2
Canadian guidelines differ: CUA recommends ultrasound as first-line even for high-risk patients 3, but this may miss upper tract lesions best seen on CT urography
Key Differences Between Guidelines
The 2025 AUA/SUFU guidelines 1 represent the most current evidence and differ from older recommendations by:
- More granular risk stratification incorporating degree of hematuria
- Specific pack-year thresholds for smoking
- Recognition that history of gross hematuria elevates risk even when current UA shows lower RBC counts
Canadian approach tends toward more conservative imaging (ultrasound over CT) 3, 4, which may reduce costs but potentially delays cancer diagnosis.
OSCE Performance Tips
Always verbalize your systematic approach:
- "I would first confirm this is true hematuria with microscopy showing ≥3 RBC/HPF"
- "I need to ask specifically about any history of visible blood in the urine"
- "I would calculate pack-years of smoking to risk-stratify"
- "Even though the patient is on warfarin, I would still pursue full evaluation"
- State the specific risk tier and corresponding evaluation plan
For intermediate/high-risk patients, state: "This patient requires both upper tract imaging and cystoscopy because microscopic hematuria has a 0.5-5% cancer risk, and most cancers are bladder cancers best detected with cystoscopy" 2.